Drug Screening

Due to the fact that EVERY protein on the Immunome Protein Array is correctly folded and functional, the results from the platform are highly reproducible and consistent.

Functional Validation – Screening kinases to demonstrate auto-phosphorylation and inhibition with small molecule inhibitors.Func

RET is auto-phosphorylated on the Immunome Protein Array.



  • Proven that proteins are actually functional on the array
  • Kinase auto-phosphorylation and inhibition with small molecule inhibitor
  • Receptor tyrosine kinase potency curves using staurosporine (40µM 0.15nM)
  • Kinase activity correlates with published data


Predictive toxicology




Determining the selectivity of drug-like molecules


Homodimer formation on array

Profiling of Immuno-toxicities

Immunotherapies have been changing the outlook for many cancer patients. Inhibition of the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) and programmed death 1 (PD1) immune checkpoints has been proven to activate the immune system. Either individually or in combination, administration of CTLA4 and PD1 inhibitors have shown promising results for the treatment of melanoma and non-small cell lung cancer.

However, as cancers are complex and diverse, what works well against one type of cancer might have little effect against another, and what works for some patients might not work for everyone. Due to this, despite its benefit, immunotherapies have been associated with immune-related adverse events (irAE), including autoimmunity. Therefore, profiling immunotherapy-related immuno-toxicity in cancer patients could serve as a tool to better predict the correct dosage and combination, as well as patient’s response to treatment. This could help lessen the effect of irAE in immunotherapies. The Immunome protein array has over 1,600 full-length, correctly folded, and functional human proteins.

The unique surface technology that underpins the Immunome protein array platform makes it ideal for various medical and therapeutic proteomics applications, including cancer biomarker and neoantigen profiling, monitoring of patient response to therapy, protein-protein interaction mapping, modulation of protein function by PTMs and mutations, and quantification of drug selectivity.